IRADIMED Corporation Reports Strong Q1 2026 Results, Declares Cash Dividend, Reaffirms 2026 Outlook
Orlando, FL – May 1, 2026 – IRADIMED Corporation (NASDAQ: IRMD), a leader in MRI-compatible medical devices, has released its financial results for the first quarter of 2026, delivering robust growth in both revenues and earnings. The company also announced a regular quarterly cash dividend and reaffirmed its financial guidance for the full year 2026, signaling continued confidence in its business trajectory.
Key Financial Highlights
- Q1 2026 revenue: \$22.0 million, up 13% from \$19.5 million in Q1 2025
- Q1 2026 GAAP diluted EPS: \$0.45, a 22% increase from \$0.37 in Q1 2025
- Q1 2026 non-GAAP diluted EPS: \$0.49, a 17% increase from \$0.42 in Q1 2025
- Net income: \$5.8 million in Q1 2026, up 24% from \$4.7 million in Q1 2025
- Record free cash flow: \$7.8 million for Q1 2026
Shareholder Returns
- Dividend declared: The Board of Directors has declared a regular quarterly cash dividend of \$0.20 per share of common stock for Q2 2026.
- Dividend details: Payable to shareholders of record as of the close of business on May 15, 2026, with payment on May 29, 2026.
2026 Guidance Reaffirmed
- Q2 2026 Guidance:
- Revenue: \$20.0 million to \$21.0 million
- GAAP diluted EPS: \$0.40 to \$0.44
- Non-GAAP diluted EPS: \$0.44 to \$0.48
- Full-Year 2026 Guidance:
- Revenue: \$91.0 million to \$96.0 million
- GAAP diluted EPS: \$1.90 to \$2.05
- Non-GAAP diluted EPS: \$2.06 to \$2.21
- Stock-based compensation expense (net of tax): Expected at \$2.4 million for the year, and \$0.6 million for Q2 2026
Balance Sheet Strength
- Cash & equivalents: \$98.5 million in total stockholders’ equity as of March 31, 2026, up from \$94.6 million at the end of 2025
- Total assets: \$114.4 million as of March 31, 2026
- Total liabilities: \$15.9 million as of March 31, 2026
Operational Performance
- Operating income: \$7.2 million in Q1 2026, up from \$5.4 million in Q1 2025
- Other income: \$532,000 in Q1 2026
- Gross margin: Not explicitly stated, but implied to be strong based on net income growth
Price-Sensitive and Shareholder-Relevant Insights
- Record EPS and Free Cash Flow: The company achieved record EPS and free cash flow, underscoring efficient operations and strong demand for its products.
- Dividend Policy: The continuation of a regular quarterly dividend signals ongoing confidence in cash generation and shareholder returns.
- Reaffirmed Guidance: By reaffirming both quarterly and full-year guidance, IRADIMED signals to the market that it is on track with its growth strategy, which may support or drive share price appreciation.
- Balance Sheet Strength: With significant cash and low liabilities, the company maintains substantial financial flexibility for M&A, R&D, or further shareholder returns.
- Upcoming Catalysts: The company referenced expectations for commercialization and ramping revenue from its next-generation 3870 MRI-compatible IV infusion pump, which could be a future growth driver.
Forward-Looking Statements and Risks
The company reminds investors that its statements regarding financial guidance, future dividends, operational plans, and product launches are forward-looking and subject to risks, including potential changes in demand, operational disruptions, competition, regulatory changes, and broader macroeconomic or geopolitical factors.
Conference Call Details
- Time: May 1, 2026, at 11:00 a.m. Eastern Time
- Webcast: Conference call registration link
- Additional information available: www.iradimed.com
Contact Information
- Phone: (407) 677-8022
- Email: [email protected]
Disclaimer: This article is for informational purposes only and does not constitute investment advice or a recommendation to buy or sell any security. Financial results and forward-looking statements are subject to change and involve risks. Investors should review the company’s filings with the SEC and consult with financial advisors before making investment decisions.
